Quick Opdivo OK In Renal Cell Carcinoma; 5th Indication
This article was originally published in Scrip
Only a week after Bristol-Myers Squibb Co. revealed the FDA had accepted the company's supplemental biologics license application for its programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab) as a treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy, regulators gave their blessing for the firm to market the drug for that use.
You may also be interested in...
At the ASCO 2016 meeting, researchers compared results for kidney cancer trials; Bristol's Opdivo gets kudos for tolerability.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.